MEDIUM confidence: 100% data completeness, but the composite (60) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $5.7B— | $6.1B+6.2% | $6.5B+7.4% | $6.9B+5.9% | $7.5B+8.5% |
| EPS (dil.) | $4.55— | $5.30+16.5% | $5.86+10.6% | $7.10+21.2% | $9.60+35.2% |
| Free Cash Flow | $370M— | $748M+102.0% | $943M+26.1% | $1.1B+12.0% | $1.3B+21.0% |
| Gross Margin | 27.9% | 29.5%+1.6pp | 29.7%+0.3pp | 31.0%+1.3pp | 31.8%+0.8pp |
| Operating Margin | 13.3% | 15.4%+2.1pp | 15.6%+0.2pp | 17.3%+1.6pp | 17.4%+0.1pp |
| Net Margin | 9.4% | 10.4%+1.0pp | 10.7%+0.3pp | 12.2%+1.5pp | 15.0%+2.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $202 avg across 4 analysts.
Buy-rated share 56% → 56% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $3.76 | $3.82 | +1.6% |
| Apr 2026 | $2.60 | $2.72 | +4.6% |
| Feb 2026 | $1.34 | $1.59 | +18.7% |
| Nov 2025 | $1.25 | $1.51 | +20.8% |
| Aug 2025 | $3.50 | $3.55 | +1.4% |
| May 2025 | $2.41 | $2.44 | +1.2% |
| Jan 2025 | $1.49 | $1.56 | +4.7% |
| Nov 2024 | $0.97 | $1.00 | +3.1% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 4.7%/yr (revenue basis).
Base free cash flow $1.1B (avg FY2024–FY2026; latest year $1.3B) · equity value $20.2B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$704K over 180 days (0 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 60 indicates a moderately attractive stock, driven by strong risk metrics and decent momentum. BR scores high on risk, with a beta of 0.9 and relatively low volatility, while its momentum is boosted by a recent 13.7% return over the past three months. However, the stock's value and growth scores are more subdued, with a P/E of 18.5 and revenue growth of 8.5%, respectively. The long-term and short-term scores are relatively aligned, with only a 3-point difference.